Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Investing Activities: 2021-2024

  • InMed Pharmaceuticals' Cash from Investing Activities rose 100.00% to -$2 in Q1 2024 from the same period last year, while for Mar 2024 it was -$887,263, marking a year-over-year decrease of 60.97%. This contributed to the annual value of -$9,293 for FY2024, which is 98.60% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Cash from Investing Activities of -$2 as of Q1 2024, which was up 99.99% from -$33,606 recorded in Q2 2023.
  • InMed Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $306,011 during Q4 2021, with a 5-year trough of -$725,457 in Q2 2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$33,606 (2023), whereas its average is -$178,163.
  • In the last 5 years, InMed Pharmaceuticals' Cash from Investing Activities crashed by 3,508.16% in 2023 and then spiked by 100.00% in 2024.
  • InMed Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at $306,011 in 2021, then reached -$725,457 in 2022, then soared by 95.37% to -$33,606 in 2023, then spiked by 100.00% to -$2 in 2024.
  • Its Cash from Investing Activities was -$2 in Q1 2024, compared to -$33,606 in Q2 2023 and -$128,198 in Q1 2023.